United States securities and exchange commission logo August 3, 2021 Manoussos Perros, Ph.D. Chief Executive Officer Entasis Therapeutics Holdings Inc. 35 Gatehouse Drive Waltham, MA 02451 Re: Entasis Therapeutics Holdings Inc. Registration Statement on Form S-3 Filed August 2, 2021 File No. 333-258371 Dear Dr. Perros: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jack S. Bodner, Esq.